Research thatreshaped strategy.
Selected engagements from our Private Equity and Healthcare & Life Sciences practices.
Would a regional accounting firm's recurring revenue survive a change of ownership, and how far can fees rise before clients leave?
After years of share loss to pouches, rigid plastics, cartons, and glass, is the movement of food out of metal cans accelerating, stabilizing, or effectively complete?
What does the US market spend on measurement and process equipment, and how do buyers actually award fabrication projects?
Would the incumbent specialty retailer's own customers actually move to a challenger paint-store concept, and on what terms?
How fast will a newly launched inhaled therapy take share from a two-format incumbent, and how much of a written script becomes paid, recurring revenue?
Is a service-led distributor gaining or losing ground with the buyers who decide, and how exposed is it to direct-from-manufacturer buying?
Demand validation for a mobile app security platform across four regions, with satisfaction and switching-risk reads on its current customers.
Purpose-built advantage holds, but consolidation risk runs three ways: GPO, ERP, and AI.
Reliable provider in a cost-led market, with a narrow window to become strategic before AI commoditizes the seat.
A multi-SKU vascular access portfolio, five markets, one adoption ceiling set by procurement friction.
Safety and logistics open the door, and earlier-line share moves toward the asset of interest through 2030.
Co-leader on usability, lagging on the capabilities that now drive retention.